Rybelsus 2 posts

• Diabetes and the third quarter of 2019
  2 November 2019  ·  Diabetes Eli Lilly Europe
  Novo Nordisk and Eli Lilly have both reported their Q3 results. Below are some of the headlines related to their diabetes business.
• Oral semaglutide (Rybelsus®) receives FDA approval for the treatment of type 2 diabetes
  20 September 2019  ·  DPP4 Eli Lilly FDA
  The FDA has issued a press release regarding the approval of the first oral GLP-1 treatment for type 2 diabetes. Novo Nordisk also issued a press release on Rybelsus®. Novo Nordisk in the US issued a separate press release. In terms of future peak sales this might be the most important FDA approval